Klaus Strebhardt

Prof. Dr. Klaus Strebhardt

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2008 in Nature Reviews Cancer
Verified
Journal Article
Closed access
KSKlaus Strebhardt
Klaus Strebhardt
AUAxel Ullrich
Axel Ullrich

1 April 2006 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
KSKlaus Strebhardt
Klaus Strebhardt
AUAxel Ullrich
Axel Ullrich

1 August 2010 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
KSKlaus Strebhardt
Klaus Strebhardt

10 January 2005 in Oncogene
Verified
Journal Article
Closed access
FEFrank Eckerdt
Frank Eckerdt
JYJuping Yuan
Juping Yuan
KSKlaus Strebhardt
Klaus Strebhardt

18 December 2002 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
BSBirgit Spänkuch-Schmitt
Birgit Spänkuch-Schmitt
JBJürgen Bereiter-Hahn
Jürgen Bereiter-Hahn
MKManfred Kaufmann
Manfred Kaufmann
KSKlaus Strebhardt
Klaus Strebhardt
Background: Expression of polo-like kinase-1 (PLK1), which has several functions in mitotic progression, is elevated in a broad range of human tumors. To investigate the role of PLK1 in neoplastic proliferation, we used the technique of RNA interference. Methods: Cells from several different cancer cell lines (MCF-7 breast cancer cells, HeLa S3 cervical cancer cells, SW-480 colon cancer cells, and A549 lung cancer cells) were transfected with small interfering (si) RNAs targeted against the human PLK1 or lamin genes. Northern and western blot analyses were used to examine PLK1 gene expression in transfected cancer cells and normal cells (human mammary epithelial cells [HMECs]). The phenotype, proliferation, and cell cycle distribution of cells transfected with siRNAs were also monitored by fluorescence microscopy and fluorescence-activated cell sorting analysis. Results: All cancer cell lines transfected with low doses of siRNAs targeted to PLK1 had greatly decreased levels of PLK1 mRNA and protein. siRNA4, which had the strongest inhibitory effect, reduced PLK1 mRNA in MCF-7 cells by 70% and PLK1 protein in MCF-7 cells by 95% 24 hours after transfection. Cell proliferation was reduced by between 66% and 99% 48 hours after transfection, and apoptosis was increased from 1%–5% to 13%–50% in transfected cells. Transfected SW-480 cells were mitotically arrested, and their centrosomes had lost the ability to nucleate microtubules. HMECs took up siRNAs less efficiently than cancer cells, and transfection with siRNAs targeted to PLK1 did not inhibit their proliferation. Conclusions: PLK1 function appears to be essential for centrosome-mediated microtubule events and, consequently, for spindle assembly. siRNAs targeted against human PLK1 may be valuable tools as antiproliferative agents that display activity against a broad spectrum of neoplastic cells at very low doses.

1 April 2020 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
RMRanadip Mandal
Ranadip Mandal
JBJoan Compte Barrón
Joan Compte Barrón
IKIzabela Kostova
Izabela Kostova
SBSven Becker
Sven Becker
KSKlaus Strebhardt
Klaus Strebhardt